Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$14.45 - HK$30.12
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$41.76B
Enterprise ValueHK$41.80B
Total Cash (Recent Filing)HK$2.97B
Total Debt (Recent Filing)HK$7.08B
Price to Earnings (P/E)23.8
Beta2.01
Next Earnings
Aug 31, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.69
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.03Price Target Upside20.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$18.64B
Bulls Say, Bears Say
Bulls Say
Integrated End-to-end CDMO/R&D ModelPharmaron’s integrated discovery-to-commercialization service model creates durable client stickiness and cross-selling opportunities. Owning capabilities across research, development and manufacturing reduces client switching, stabilizes revenue mix, and supports multi-year contracts typical in CDMO economics.
Low Leverage, Strengthening Balance SheetA low TTM debt-to-equity (~0.23) and growing shareholders’ equity provide financial flexibility and resilience. This reduces refinancing and interest-rate stress, supports capital spending on labs and plants, and preserves the ability to honor long-term client supply agreements during industry cycles.
Sustained Operating ProfitabilityReported TTM net and EBIT margins indicate sustained underlying profitability. Healthy margins support reinvestment in capabilities and talent, fund necessary compliance and capacity upgrades, and provide a buffer versus industry cyclicality, underpinning long-term service quality and client retention.
Bears Say
Weak, Volatile Free Cash Flow ConversionOperating cash flow covers only ~39% of net income and free cash flow is small and fell sharply (~-46% TTM). Persistent weak, volatile cash conversion limits internal funding for capex and working capital, increasing reliance on external financing and reducing financial flexibility over the medium term.
Slowing Revenue Growth TrajectoryTTM revenue growth has slowed to around 3.2% from earlier faster expansion. Slower top-line growth can hinder scale benefits, constrain margin recovery and returns, and may reflect intensifying competition or market saturation in core service lines, affecting medium-term growth momentum.
Margin Compression From Historical PeaksMargins have meaningfully compressed versus 2021, indicating structural headwinds such as cost inflation, pricing pressure, or adverse mix shifts. Sustained margin erosion reduces free cash generation, curtails reinvestment capacity, and weakens returns on invested capital over multiple quarters.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.45 and its highest was HK$30.12 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$41.76B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 79 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.212 earnings per share for the quarter, missing the consensus estimate of HK$0.24 by -HK$0.028.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.207 which represents an annual dividend yield of 1.04%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.29.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.212 in its last earnings report, missing expectations of HK$0.24. Following the earnings report the stock price went up 5.922%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
11.22%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a global contract research, development, and manufacturing organization (CRDMO) that supports the life sciences sector. Operating across North America, Europe, Mainland China, and other Asian regions, the company delivers comprehensive pharmaceutical research and development services worldwide. Its diverse operations are structured into five key divisions: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Solutions; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and an "Others" category. Within its offerings, Pharmaron provides extensive laboratory support, including expertise in medicinal, synthetic, analytical, and purification chemistry, alongside computer-aided drug design. It also offers bioscience solutions such as in vitro and in vivo drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME) studies, as well as in vitro biology, in vivo pharmacology, and safety assessment, including specialized U.S. laboratory services. The company's CMC capabilities encompass process development, manufacturing, material science, pre-formulation, formulation development, manufacturing, and analytical development services. Additionally, it handles radiolabelled science and manages both early-stage clinical trials and broader clinical research with site management. Pharmaron also engages in business development and offers comprehensive contract research, development, and manufacturing for various pharmaceutical products. Established in 2004, Pharmaron Beijing Co., Ltd. is headquartered in Beijing, People's Republic of China.
3759 Stock 12 Month Forecast
Average Price Target
HK$29.03
▲(20.25% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---